Daren Wilson
Co-Founder, Senior Partner
Commercial engagements and venture partnerships. 28 years in pharmaceutical leadership.
Swiss healthcare venture studio and commercialisation partner
First revenue in your next market.
HealthSeed takes approved health products to their first paying customers abroad, and builds the companies the market has not.
- Clear strategy
- Regulatory pathway
- Market access
- Paying customers
- New markets
The problem
Approval opens the door. Revenue is decided country by country.
Companies often stall in one of four places after approval.
- Which country first?
Every market has its own route to payment.
- Who pays, and for what evidence?
Payers ask for proof the approval did not need.
- A pilot with no purchase order
Hospitals trial, then stop at procurement.
- Investors want revenue first
Follow-on capital waits for paying customers.
How HealthSeed works
One studio, three ways we create value.
Commercialisation earns today, the ventures we build are the long game, and the network feeds both.
Pillar 1
International healthcare commercialisation
The Launchpad and the Foundations, Intelligence, and Communications services take approved products to revenue in new markets.
See the LaunchpadPillar 2
Joint ventures and AI products
Where the science is exceptional and the company is not ready, we build alongside it. Ventures so far: Venitara (announced 15 September 2026) and ZINOS, both live.
See our venturesPillar 3
Expert ecosystem and network
Our specialists and around ten Network Partners supply talent, deal flow, and market access.
Meet the networkPillar 1 · The Launchpad
One team from approval to first purchase order.
Six phases, run with your team, with milestones and evidence agreed with your board before work starts.
- First market chosen
- EU representation in place
- Payer route confirmed
- Pilot signed
- First purchase order
- Your team runs it
US into Europe is open now. Europe into the US is in preparation, and MENA partnerships are under way.
The people
A Senior Partner leads every engagement.
Operators from Roche, Novartis, and MSD.
Safia Agueni
Co-Founder, Senior Partner
Leads adoption, governance, and the partner network. 18+ years in pharma and AI-enabled diagnostics.
- 46+years combined at Roche, Novartis, and MSD
- 35+Expert Community specialists
Insights
What we are seeing in the market.
Your innovation deserves to succeed.
Answer six questions and see an indicative route. If we can help, you can book a Senior Partner.
Plan your launch